AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28641912 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirited Life intervention (2-year multicomponent health intervention including personal goal setting, monthly health coaching, online weight loss intervention, small grant, and workshops)
Number of subjects: 1114
Study 28641912 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirited Life intervention
Number of subjects: 1114
Study 28641912 — intervention group
Group type: COMPARATOR
Intervention: 1-year waitlist control
Number of subjects: 1114
Study 28641912 — intervention group
Group type: COMPARATOR
Intervention: 2-year waitlist control
Number of subjects: 1114
Study 25212521 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based virtual reality system used for rehabilitation of the upper limb following stroke, advised to use 3 times a day for 20 minutes over 8 weeks.
Number of subjects: 17
Study 25212521 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based virtual reality system
Number of subjects: 17
Study 23570567 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-tailored print (CTP) intervention
Number of subjects: 168
Study 23570567 — intervention group
Group type: COMPARATOR
Intervention: Generic print (GP) pamphlet
Number of subjects: 168
Study 21623982 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 50 mg administered 30 min before bedtime for 7 days
Number of subjects: 16
Study 21623982 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 16
Study 21623982 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone on day 7
Number of subjects: 16
Study 21623982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18274739 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAPPA (acceleration factor 2, time reduction approximately 50%)
Number of subjects: 25
Study 18274739 — intervention group
Group type: COMPARATOR
Intervention: Non-accelerated MRI
Number of subjects: 25
Study 16792770 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 1.0 mg kg‐1 once weekly for 12 weeks
Number of subjects: 793
Study 16792770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study 14509553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nozovent (nasal valve dilator)
Number of subjects: 38
Study 12125616 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone injections
Number of subjects: 0
Study 12125616 — intervention group
Group type: COMPARATOR
Intervention: Normal testosterone levels
Number of subjects: 0
Study 9358933 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (specifics not provided)
Number of subjects: 0
Study 9358933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytotoxic treatment
Number of subjects: 0
Study 9358933 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised QL form
Number of subjects: 0
Study 1287015 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of famotidine (Group 3)
Number of subjects: 126
Study 1287015 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of famotidine (Group 6)
Number of subjects: 126
Study 1287015 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of diphenhydramine (Group 2)
Number of subjects: 126
Study 1287015 — intervention group
Group type: COMPARATOR
Intervention: No drugs (Group 1)
Number of subjects: 126
Study 1287015 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group 5)
Number of subjects: 126
Study 4075934 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal caffeine ingestion (500 mg/day)
Number of subjects: 11
Study 4075934 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (5 cups/day)
Number of subjects: 11
Study 30165610 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg, 150 mg, or 300 mg subcutaneously once every 3 months
Number of subjects: 4833
Study 30165610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4833
Study 28821264 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Access to ART for All (EAAA)
Number of subjects: 4501
Study 28821264 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 4501
Study 26304967 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coaching plus brief education
Number of subjects: 424
Study 26304967 — intervention group
Group type: COMPARATOR
Intervention: Brief education alone
Number of subjects: 424
Study 23210563 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostatic air filter
Number of subjects: 37
Study 23210563 — intervention group
Group type: COMPARATOR
Intervention: Placebo filter
Number of subjects: 37
Study 21251861 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, progressive exercise training and dietary counseling for 48 weeks
Number of subjects: 21
Study 21251861 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 21
Study 18453793 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-item medication adherence scale
Number of subjects: 1367
Study 16540560 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus cyclosporine A (Pred+CsA)
Number of subjects: 104
Study 16540560 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (Pred)
Number of subjects: 104
Study 12649700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg bid
Number of subjects: 8
Study 12649700 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 11400948 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200-800 mg/day)
Number of subjects: 54
Study 9489600 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir, 1000 mg, given alone
Number of subjects: 12
Study 9489600 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir, 1000 mg, given with digoxin
Number of subjects: 12
Study 9489600 — intervention group
Group type: COMPARATOR
Intervention: Digoxin given alone
Number of subjects: 12
Study 9489600 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin given with valaciclovir (1000 mg three times/day for 8 days)
Number of subjects: 12
Study 7875274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg
Number of subjects: 14
Study 7875274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 14
Study 7875274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3361221 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg twice daily
Number of subjects: 0
Study 3361221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29098392 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (6 µg/kg/h over 10 min followed by 0.2‐0.7 µg/kg/h)
Number of subjects: 16
Study 29098392 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (initial target of 1.5 ng/ml using the Dyck model)
Number of subjects: 16
Study 28131072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 40
Study 28131072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25450124 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in depressive symptoms over the course of a 12-week trial
Number of subjects: 124
Study 25450124 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in depressive symptoms
Number of subjects: 124
Study 25450124 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived functional disability
Number of subjects: 124
Study 25450124 — intervention group
Group type: EXPERIMENTAL
Intervention: Life satisfaction and mental well-being
Number of subjects: 124
Study 25450124 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical well-being
Number of subjects: 124
Study 23253744 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional blood pressure control rate (fixed BP target <140/90)
Number of subjects: 3355
Study 23253744 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR-adjusted blood pressure control rate (BP target <130/80 for very high CVR, <140/90 for high CVR, <160/100 for low CVR)
Number of subjects: 3355
Study 23253744 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional blood pressure control rate
Number of subjects: 3355
Study 23253744 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR-adjusted blood pressure control rate
Number of subjects: 3355
Study 21206288 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Smith-Petersen approach
Number of subjects: 48
Study 21206288 — intervention group
Group type: COMPARATOR
Intervention: Hardinge approach
Number of subjects: 48
Study 21206288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 48
Study 17412363 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 20
Study 17412363 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 20
Study 17412363 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 20
Study 17412363 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol and Risperidone
Number of subjects: 20
Study 16441950 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (50 mg/d)
Number of subjects: 117
Study 16441950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 12664086 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate
Number of subjects: 489
Study 12664086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 10474766 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-ROM program based on the 'Sunny Days, Healthy Ways' curriculum
Number of subjects: 162
Study 8764120 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular milk products (calcium, 30 mM)
Number of subjects: 13
Study 8764120 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk products (calcium, 3 mM)
Number of subjects: 13
Study 2059973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrices containing 1,000, 1,500, and 2,500 micrograms fluoride per gram as sodium monofluorophosphate
Number of subjects: 0
Study 2059973 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study 6282434 — intervention group
Group type: EXPERIMENTAL
Intervention: MER (methanol-extraction residue of Bacillus Calmette-Guerin) 400 mcg intradermally every six weeks
Number of subjects: 102
Study 6282434 — intervention group
Group type: COMPARATOR
Intervention: No MER (control group)
Number of subjects: 102
Study 6282434 — intervention group
Group type: EXPERIMENTAL
Intervention: MER
Number of subjects: 102
Study 30536595 — intervention group
Group type: COMPARATOR
Intervention: sacubitril/valsartan 200 mg
Number of subjects: 1438
Study 30536595 — intervention group
Group type: COMPARATOR
Intervention: sacubitril/valsartan 400 mg
Number of subjects: 1438
Study 30536595 — intervention group
Group type: COMPARATOR
Intervention: sacubitril/valsartan 200 mg and 400 mg
Number of subjects: 1438
Study 29138199 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosclerotherapy (EST)
Number of subjects: 20
Study 29138199 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin sclerotherapy without electroporation
Number of subjects: 20
Study 29138199 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 20
Study 26574019 — intervention group
Group type: EXPERIMENTAL
Intervention: OLIVE
Number of subjects: 458
Study 26574019 — intervention group
Group type: COMPARATOR
Intervention: SOYBEAN
Number of subjects: 458
Study 24294604 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser (450 mW, 830 nm combined Ga‐Al‐As diode laser)
Number of subjects: 48
Study 24294604 — intervention group
Group type: COMPARATOR
Intervention: Placebo irradiation
Number of subjects: 48
Study 20673556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 60
Study 18438241 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and plyometric training (Group ST+P)
Number of subjects: 21
Study 18438241 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (Group ST)
Number of subjects: 21
Study 18438241 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 to 8 soccer sessions a week)
Number of subjects: 21
Study 18438241 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention group (ST and ST+P pooled)
Number of subjects: 21
Study 18438241 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 16546743 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human epithelial growth factor (rhEGF)
Number of subjects: 48
Study 16546743 — intervention group
Group type: COMPARATOR
Intervention: 500 kHz high‐frequency electromagnetic wave
Number of subjects: 48
Study 15087598 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5337
Study 10955425 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring plasma glucose up to four times daily
Number of subjects: 70
Study 10955425 — intervention group
Group type: COMPARATOR
Intervention: No monitoring of plasma glucose
Number of subjects: 70
Study 9003479 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP
Number of subjects: 175
Study 9003479 — intervention group
Group type: COMPARATOR
Intervention: ProMACE‐CytaBOM
Number of subjects: 175
Study 1794889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-fortified milk formula
Number of subjects: 130
Study 1794889 — intervention group
Group type: COMPARATOR
Intervention: Standard milk formula
Number of subjects: 130
Study 6337655 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose bolus 6‐methylprednisolone (BMPr) at 20 mg/kg/day i.v. for the first 3 days, 10 mg/kg/day i.v. for the following 4 days, then tapered to 1 mg/kg/day.
Number of subjects: 19
Study 6337655 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose bolus 6‐methylprednisolone (BMPr)
Number of subjects: 19
Study 2874773 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied betamethasone valerate
Number of subjects: 0
Study 31462688 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mean total activity
Number of subjects: 886
Study 31462688 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LPA
Number of subjects: 886
Study 31462688 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline total MVPA
Number of subjects: 886
Study 31462688 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline long-bout MVPA
Number of subjects: 886
Study 31462688 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline weight
Number of subjects: 886
Study 29987746 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTF) therapy
Number of subjects: 106
Study 29987746 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide alone
Number of subjects: 106
Study 27543472 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil (Group I)
Number of subjects: 200
Study 27543472 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (Group II)
Number of subjects: 200
Study 24756515 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.1 mg/kg IV, repeat at 5 minutes if necessary)
Number of subjects: 273
Study 24756515 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.2 mg/kg IV, repeat at 5 minutes if necessary)
Number of subjects: 273
Study 24756515 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.1 mg/kg IV)
Number of subjects: 273
Study 24756515 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.2 mg/kg IV)
Number of subjects: 273
Study 22882126 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel complex of lipophilic ingredients (cetyl alcohol, isostearyl isostearate, potassium cetyl phosphate, cetyl behenate, behenic acid)
Number of subjects: 0
Study 22882126 — intervention group
Group type: COMPARATOR
Intervention: Comparable mineral oil-containing vehicle
Number of subjects: 0
Study 21094360 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-fenofibrate combinations
Number of subjects: 584784
Study 21094360 — intervention group
Group type: COMPARATOR
Intervention: Statins alone
Number of subjects: 584784
Study 18685046 — intervention group
Group type: EXPERIMENTAL
Intervention: Midgait method
Number of subjects: 0
Study 18685046 — intervention group
Group type: COMPARATOR
Intervention: Two-step method
Number of subjects: 0
Study 15920040 — intervention group
Group type: COMPARATOR
Intervention: Algorithm 1 (investigator led)
Number of subjects: 4961
Study 15920040 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm 2 (performed by study subjects)
Number of subjects: 4961
Study 15920040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both algorithms
Number of subjects: 4961
Study 12524668 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g glucose given to fed subjects
Number of subjects: 13
Study 12524668 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g glucose given to 4-day-fasted subjects
Number of subjects: 13
Study 12524668 — intervention group
Group type: EXPERIMENTAL
Intervention: 33 g glucose in OGTT for 13-hour-fasted subjects
Number of subjects: 13
Study 12524668 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g glucose in OGTT for 13-hour-fasted subjects
Number of subjects: 13
Study 10472349 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/Irinotecan at dose level 1 (20/25 mg/m2)
Number of subjects: 12
Study 10472349 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/Irinotecan at dose level 2 (20/40 mg/m2)
Number of subjects: 12
Study 10472349 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/Irinotecan at dose level 3 (25/55 mg/m2)
Number of subjects: 12
Study 10472349 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Docetaxel/Irinotecan with radiotherapy)
Number of subjects: 12
Study 8622389 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg three times daily)
Number of subjects: 81
Study 8622389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8622389 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 81
Study 2060716 — intervention group
Group type: EXPERIMENTAL
Intervention: High fasting plasma insulin concentration and low 2-h plasma insulin concentration after a glucose load
Number of subjects: 5042
Study 2060716 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance with elevated fasting plasma glucose
Number of subjects: 5042
Study 2060716 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance based on 2-h postload glucose
Number of subjects: 5042
Study 7070890 — intervention group
Group type: EXPERIMENTAL
Intervention: Convectively heated incubator
Number of subjects: 16
Study 7070890 — intervention group
Group type: COMPARATOR
Intervention: Open radiant warmer
Number of subjects: 16
Study 31877631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose ingested
Number of subjects: 21
Study 31877631 — intervention group
Group type: COMPARATOR
Intervention: Sham-fed sucralose
Number of subjects: 21
Study 31877631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 21
Study 29106034 — intervention group
Group type: EXPERIMENTAL
Intervention: BIP CVC
Number of subjects: 34
Study 29106034 — intervention group
Group type: COMPARATOR
Intervention: Standard CVC
Number of subjects: 34
Study 26890014 — intervention group
Group type: EXPERIMENTAL
Intervention: SubQ ADD-ON
Number of subjects: 52
Study 26890014 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 25027821 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist protocol
Number of subjects: 60
Study 25027821 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 60
Study 22760800 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal cross-linking procedure
Number of subjects: 39
Study 22760800 — intervention group
Group type: COMPARATOR
Intervention: 0.1% riboflavin (w/v) eyedrops in 20% dextran solution for 1 month
Number of subjects: 39
Study 20667082 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-strengthening program with load (50 to 70% of 1RM), three times per week for ten weeks
Number of subjects: 26
Study 20667082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no new activities during the initial study period)
Number of subjects: 26
Study 17993041 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200, 300, or 400 mg once daily for up to 12 weeks
Number of subjects: 1529
Study 17993041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1529
Study 17993041 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 1529
Study 15598674 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d, n = 25)
Number of subjects: 52
Study 15598674 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg three times daily, n = 27)
Number of subjects: 52
Study 11388521 — intervention group
Group type: EXPERIMENTAL
Intervention: Low remifentanil (0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 10
Study 11388521 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate remifentanil (0.15 microg x kg(‐1) x min(‐1))
Number of subjects: 10
Study 11388521 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 10
Study 9241305 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine device (20 micrograms/day)
Number of subjects: 70
Study 9241305 — intervention group
Group type: COMPARATOR
Intervention: Endometrial resection
Number of subjects: 70
Study 8427821 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betamethasone-17-valerate
Number of subjects: 0
Study 3669078 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication Technique Training
Number of subjects: 20
Study 3669078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual Technique Training
Number of subjects: 20
Study 3669078 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Treatment
Number of subjects: 20
Study 3669078 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention‐Placebo
Number of subjects: 20
Study 3669078 — intervention group
Group type: COMPARATOR
Intervention: No‐Treatment
Number of subjects: 20
Study 31043129 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load resistance training (HL-RT, e.g. 70% of 1 repetition-maximum, 1RM)
Number of subjects: 10